Premium
HIGH EFFICACY OF VENETOCLAX PLUS OBINUTUZUMAB IN PATIENTS WITH COMPLEX KARYOTYPE (CKT) AND CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): A PROSPECTIVE ANALYSIS FROM THE CLL14 TRIAL
Author(s) -
AlSawaf O.,
Lilienweiss E.,
Bahlo J.,
Robrecht S.,
Fink A.,
Patz M.,
Tandon M.,
Humphrey K.,
Jiang Y.,
Schary W.,
Porro Lurà M.,
Ritgen M.,
Tausch E.,
Stilgenbauer S.,
Eichhorst B.,
Fischer K.,
Hallek M.,
Kreuzer K.
Publication year - 2019
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.68_2629
Subject(s) - medicine , venetoclax , obinutuzumab , hazard ratio , regimen , chlorambucil , gastroenterology , proportional hazards model , ighv@ , oncology , confidence interval , chronic lymphocytic leukemia , chemotherapy , leukemia , cyclophosphamide